Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Beta-lactam antibiotics as a possible novel therapy for managing epilepsy in autism, a case report and review of literature Abstract Autism is a disorder with unknown etiology. There are only a few FDA approved medications for treating of autism. Co-occurring of autism and epilepsy is common. Glutamate antagonists improve some symptoms of autism. Ceftriaxone, a beta-lactam antibiotic, increases the expression of glutamate transporter 1 which decreases extracellular glutamate level. Current literature hypothesized that modulating astrocyte glutamate transporter expression by ceftriaxone or cefixime might improve some symptoms of autism. This is a case report of a child with autism and epilepsy that seizures are decreased after taking cefixime Keywords: Autistic Disorder, cefixime, Anti-Bacterial Agents, glutamates, Membrane Transport Proteins, Therapeutics, inflammation, epilepsy. 1 Introduction Autism is a complex disorder with the impairment of verbal communications, social relationship problems, repetitive behaviors, and restrictive interests. Its etiology is not clearly known and there is a debate about its mechanisms of pathogenesis. There is no cure for autism. So, novel therapeutic interventions for treating autism are highly needed. Meanwhile, autism is highly comorbid with epilepsy (OR=22.2; 95% CI=16.8-29.3) (Selassie, Wilson et al. 2014). Nevertheless, treatment refractory epilepsy in autism is up to 33.9% (Sansa, Carlson et al. 2011). in addition, surgical and agus nerve stimulator (VNS) implantation outcomes in the patients with both autism and epilepsy are less effective than in other treatment refractory epilepsy patients (Sansa, Carlson et al. 2011). The beta-lactam antibiotics of cefixime and ceftriaxone are from third-generation cephalosporin. Ceftriaxone increases GLT1/EAAT2 expression (Nizzardo, Nardini et al. 2011). Glutamate neurotoxicity may contribute as a pathological mechanism for autism (Harada, Taki et al. 2010). There is an abnormality of GABA to glutamate ratio (Harada, Taki et al. 2010) or imbalance of the inhibitory to excitatory systems in the neurobiology of autism (Polleux and Lauder 2004). Glutamate synthesis inhibition attenuates the neurotoxic activity in Rett’s syndrome (Maezawa and Jin 2010). It is suggested that the factors which attenuate the hyperglutaminergic state in autism may improve its symptoms (Ghanizadeh 2010). Also, improving GABAergic system is proposed to be effective (Ghanizadeh 2010). Glutamate is a crucial neurotransmitter in the brain. It is released from cells into extracellular fluid and then removed by glutamate transporters. This transportation contributes the controlling of excitatory synaptic transmissions. 2 The excitatory amino acid transporter of EAAT2 (or GLT1) is one of the main glutamate transporters in brain. About 90% of glutamate transporters in brain are EAAT2 (Yamada, Kawahara et al. 2006). Excitatory amino acid transporters keep the extracellular glutamate level less than the neurotoxic level and GLT-1 is the major determinant of glutamate level in extracellular fluid. The decreased expression and function of astrocyte glutamate transporters enhances the levels of extracellular glutamate in epilepsy and Tuberous Sclerosis Complex (Zeng, Ouyang et al. 2007). Tuberous Sclerosis Complex is usually co-morbid with epilepsy and autism. Astrocyte glutamate transporters are deficient in animal models of epilepsy in Tuberous Sclerosis Complex (Zeng, Bero et al. 2010). This abnormality is also reported in human and animal models of epilepsy. In addition, targeting astrocytic mechanisms has been introduced as a novel treatment approach for epilepsy and TSC (Zeng, Bero et al. 2010). Cefixime is a beta lactam antibiotic. Ceftriaxone is also a beta lactam antibiotic improves expression of glutamate transporter (GLT-1) (Nizzardo, Nardini et al. 2011) . These transporters play an important role in vitro and in vivo for preventing of glutamate neurotoxicity. Ceftriaxone decreases extracellular glutamate level by the enhancement of astrocyte glutamate transporters expression (Zeng, Bero et al. 2010). In addition, ceftriaxon toxicity is very low. A recently published study showed that ceftriaxone is neuroprotective during the acute phase of ischemia (Kim and Jones 2012). Already, the antagonism of glutamate receptors has been suggested for treatment of autism. However, regulating glutamate transporter expression and activity has this advantage that it minimizes the pathological impact from a glutamate overload while keeping the glutamate 3 physiological role. Of course, it is not clear whether the transporter of extracellular glutamate level is decreased. Case presentation The patient is a 9 year old boy with autism spectrum disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). He suffers from generalized tonic clonic epilepsy from age 4 years. He has taken different medications such as phenobarbital, sodium valporate, and carbamazepine with sufficient dosages and durations. However, epilepsy has never been controlled favorably. According to his parents’ report, the patient took cefixime 200mg/day to control diarrhea about 2 years ago. The seizure episodes were dramatically decreased 3 days after starting the medication while the there was no change in anti-epileptic medication regime. The seizure episodes were controlled for about 5 months. Then, the number of seizure episodes increased. His highly educated parents administered cefixime 200mg/day to control seizure again. They reported that seizure attacks were controlled markedly after taking cefixime for three days. The patient was not febrile while the medication trials were administered. Both parents reported that they repeated this trial for several times to control the seizure episodes in the recent years. The epilepsy was controlled in all of the trials after taking cefixime for 3 to 5 days. Then, they discontinued cefixime after 7 days. They reported that there is a marked decreased in seizure attacks number and aggressive behaviors. Physical examination did not show any other remarkable finding such as fever, headache, and photophobia. Brain MRI did not any abnormal finding. No remarkable finding was found in laboratory examination. This is a case report. His parents provided their consent for publication of this report. 4 Discussion Neuroinflammation is proposed to have a contribution in neurobiology both autism and epilepsy (Ghanizadeh 2011, Ghanizadeh 2011, Ghanizadeh 2012, Ghanizadeh 2012). Recently, antiinflammatory and immunosuppressive drugs showed some promising therapeutic effects for autism (Asadabadi, Mohammadi et al. 2012) and epilepsy. For example, some antibiotics as doxycycline or minocycline or tetracycline protect against seizures in experimental seizure models in rats and mice (Wang, Englot et al. 2012). However, Clavulanic acid, which inhibits bacterial b –lactamases did not affect convulsions in acute seizure tests in mice (Gasior, Socala et al. 2012). In several trials, cefixime was administered without any co-administered medication. Therefore, no drug interaction was an explanation for this association. A few days seizure control cannot be attributed to short course of cefixime but the patient experiences several consequent episodes of seizure before administering cefixime. After administering cefixime, the several episodes of seizure were stopped. Whenever, cefixime was not administered the episode of seizure happened again. Seizures induce brain inflammation and interleukin (IL)-1β damaging Blood brain barrier (Librizzi, Noe et al. 2012). Some antibiotics such as minocycline may decrease the epileptic seizure through anti-inflammatory effects (Beheshti Nasr, Moghimi et al. 2013). this effect can be a possible explanation for the effect of cefixime on epilepsy. In view of the limited number of treatment approaches for autism, the proposed role of glutamate in pathophysiology of autism (Polleux and Lauder 2004), the promising efficacy of the antagonism of glutamate receptors for treatment of autism (Erickson, Posey et al. 2007), the 5 excitatory amino acid transporters role for keeping extracellular glutamate level less than the neurotoxic levels , the increase of expression of glutamate transporter (GLT-1) by ceftriaxone (Nizzardo, Nardini et al. 2011), according to the evidence, it seems to be reasonable to hypothesize that modulating astrocyte glutamate transporter expression by ceftriaxone or cefixime might be even at least partially effective treating approach for autism and epilepsy. Of course, overexpression in vesicular glutamate transporter levels in Drosophila causes excess glutamate release in which leads to excitotoxicity. So, the targeting of glutamate transporters should be highly specific and intelligent. The level of glutamate is increased in autism and it is propsed as a target for treating autism. Therefore, targeting glutamate by the antibiotic might be effective for treating both autism and seizure. Well controlled clinical trials are recommended to examine the effect of beta lactam antibiotics on the animal models of autism plus epilepsy. It needs to be reminded that at least Cefepime, a fourth-generation cephalosporin antibiotic, is associated with sezuire in some reports (Thabet, Al Maghrabi et al. 2009). Of course, further studies should use more objective measures such as EEG monitoring and blood drug concentration assessment. So, this report should be considered as a preliminary report. 6 References Asadabadi, M., M. R. Mohammadi, A. Ghanizadeh, A. Modabbernia, M. Ashrafi, E. Hassanzadeh, S. Forghani and S. Akhondzadeh (2012). "Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial." Psychopharmacology (Berl). Beheshti Nasr, S. M., A. Moghimi, M. Mohammad-Zadeh, A. Shamsizadeh and S. M. Noorbakhsh (2013). "The effect of minocycline on seizures induced by amygdala kindling in rats." Seizure 22(8): 670-674. Erickson, C. A., D. J. Posey, K. A. Stigler, J. Mullett, A. R. Katschke and C. J. McDougle (2007). "A retrospective study of memantine in children and adolescents with pervasive developmental disorders." Psychopharmacology (Berl) 191(1): 141-147. Gasior, M., K. Socala, D. Nieoczym and P. Wlaz (2012). "Clavulanic acid does not affect convulsions in acute seizure tests in mice." J Neural Transm 119(1): 1-6. Ghanizadeh, A. (2010). "Targeting neurotensin as a potential novel approach for the treatment of autism." J Neuroinflammation 7(1): 58. Ghanizadeh, A. (2010). "Transplantation of GABAergic cell line as a novel hypothesized treatment for autism " Epilepsy & Behavior. Ghanizadeh, A. (2011). "Could fever and neuroinflammation play a role in the neurobiology of autism? A subject worthy of more research." Int J Hyperthermia 27(7): 737-738. Ghanizadeh, A. (2011). "May lovastatin target both autism and epilepsy? A novel hypothesized treatment." Epilepsy Behav 20(2): 422. Ghanizadeh, A. (2012). "Hydrogen as a novel hypothesized emerging treatment for oxidative stress in autism." Eur Rev Med Pharmacol Sci 16(9): 1313-1314. 7 Ghanizadeh, A. (2012). "Physical exercise and intermittent administration of lactulose may improve autism symptoms through hydrogen production." Med Gas Res 2(1): 19. Harada, M., M. M. Taki, A. Nose, H. Kubo, K. Mori, H. Nishitani and T. Matsuda (2010). "NonInvasive Evaluation of the GABAergic/Glutamatergic System in Autistic Patients Observed by MEGA-Editing Proton MR Spectroscopy Using a Clinical 3 Tesla Instrument." J Autism Dev Disord. Kim, S. Y. and T. A. Jones (2012). "The effects of ceftriaxone on skill learning and motor functional outcome after ischemic cortical damage in rats." Restor Neurol Neurosci. Librizzi, L., F. Noe, A. Vezzani, M. de Curtis and T. Ravizza (2012). "Seizure-induced brainborne inflammation sustains seizure recurrence and blood-brain barrier damage." Ann Neurol 72(1): 82-90. Maezawa, I. and L. W. Jin (2010). "Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate." J Neurosci 30(15): 5346-5356. Nizzardo, M., M. Nardini, D. Ronchi, S. Salani, C. Donadoni, F. Fortunato, G. Colciago, M. Falcone, C. Simone, G. Riboldi, A. Govoni, N. Bresolin, G. P. Comi and S. Corti (2011). "Betalactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms." Exp Neurol. Polleux, F. and J. M. Lauder (2004). "Toward a developmental neurobiology of autism." Ment Retard Dev Disabil Res Rev 10(4): 303-317. Sansa, G., C. Carlson, W. Doyle, H. L. Weiner, J. Bluvstein, W. Barr and O. Devinsky (2011). "Medically refractory epilepsy in autism." Epilepsia 52(6): 1071-1075. 8 Selassie, A. W., D. A. Wilson, G. U. Martz, G. G. Smith, J. L. Wagner and B. B. Wannamaker (2014). "Epilepsy beyond seizure: a population-based study of comorbidities." Epilepsy Res 108(2): 305-315. Thabet, F., M. Al Maghrabi, A. Al Barraq and B. Tabarki (2009). "Cefepime-induced nonconvulsive status epilepticus: case report and review." Neurocrit Care 10(3): 347-351. Wang, D. D., D. J. Englot, P. A. Garcia, M. T. Lawton and W. L. Young (2012). "Minocyclineand tetracycline-class antibiotics are protective against partial seizures in vivo." Epilepsy Behav 24(3): 314-318. Yamada, T., K. Kawahara, T. Kosugi and M. Tanaka (2006). "Nitric oxide produced during sublethal ischemia is crucial for the preconditioning-induced down-regulation of glutamate transporter GLT-1 in neuron/astrocyte co-cultures." Neurochem Res 31(1): 49-56. Zeng, L. H., A. W. Bero, B. Zhang, D. M. Holtzman and M. Wong (2010). "Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex." Neurobiol Dis 37(3): 764-771. Zeng, L. H., Y. Ouyang, V. Gazit, J. R. Cirrito, L. A. Jansen, K. C. Ess, K. A. Yamada, D. F. Wozniak, D. M. Holtzman, D. H. Gutmann and M. Wong (2007). "Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex." Neurobiol Dis 28(2): 184-196. 9